长效红细胞生成刺激剂治疗肾性贫血中国专家共识(2024年版)  

Chinese expert consensus on long-acting erythropoiesis-stimulating agents in the treatment of renal anemia(2024)

作　　者：中国非公立医院协会肾病透析专业委员会共识专家组 刘必成[2] 梅长林 蒋红利[4] 姚丽[5] Expert Committee of Nephrology&Dialysis Branch of China Non-Government Medical Institutions Association;Liu Bicheng;Mei Changlin(不详;Institute of Nephrology,Zhongda Hospital,Southeast University,Nanjing 210009,China;Department of Nephrology,Changzheng Hospital,Second Military Medical University,Shanghai 200003,China)

机构地区：[1]不详 [2]东南大学附属中大医院肾脏病科,南京210009 [3]海军军医大学第二附属医院(上海长征医院)肾脏病科,上海200003 [4]西安交通大学第一附属医院 [5]中国医科大学附属第一医院

出　　处：《中华肾脏病杂志》2024年第2期146-157,共12页Chinese Journal of Nephrology

摘　　要：红细胞生成刺激剂(erythropoiesis⁃stimulating agents,ESAs)是临床上治疗肾性贫血的常用药物,目前可供临床医师选择的有短效ESAs和长效ESAs。短效ESAs在我国已广泛使用,历史悠久,国内外有众多指南共识。长效ESAs具有半衰期长、输注频次低、患者治疗依从性好等优势,近年来临床研究取得重要进展,但是尚缺乏长效ESAs临床规范使用的指导意见。为此,中国非公立医院协会肾病透析专业委员会组织相关专家制定了《长效红细胞生成刺激剂治疗肾性贫血中国专家共识》,本共识主要介绍了长效ESAs的分类、作用机制与药效学特点,在肾性贫血治疗中应用的适应证、时机、方案,特殊人群应用,不良反应及处理等,以指导长效ESAs类药物在肾性贫血治疗中的规范化使用。Erythropoiesis-stimulating agents(ESAs)are commonly used drugs in the treatment of renal anemia.There are currently two types of ESAs available to clinicians,including short-acting ESAs and long-acting ESAs.Short-acting ESAs have been used for decades in China,which are being widely accepted nowadays.Several professional societies have published consensus guidelines for the use and interpretation of short-acting ESAs worldwide in recent years.The advantages of long-acting ESAs include long half-life,low infusion frequency,good patient compliance,etc.There is still a lack of guidance on the clinical use of long-acting ESAs although important progress of long-acting ESAs has been made in clinical trials in recent years.Thus,the Society of Nephrology&Dialysis of China Non-Government Medical Institutions Association organized relevant experts to jointly formulate the"Chinese Expert Consensus on Long-acting ESAs in the Treatment of Renal Anemia".This consensus mainly introduces the classification,mechanism of action and pharmacological characteristics of long-acting ESAs,their indications,timing,administration protocols,application in special populations,adverse reactions and management in renal anemia.It is the hope of this concensus will guide the clinical use of long-acting ESAs in the treatment of renal anemia.

关 键 词：慢性肾脏病 肾性贫血 长效红细胞生成刺激剂 专家共识 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]